Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Aterixen Tablets vs Film-Coated Tablets in Healthy Volunteers
NCT06096571Phase 1Not yet recruiting
- Sponsor
- Valenta Pharm
- Start
- Jun 2024
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of aterixen in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Valenta Pharm. Primary endpoints: Maximum Plasma Concentration, Time to Maximum Plasma Concentration and 8 more. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
aterixen
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT06096571.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06096571.